(2-[2]furyl-ethyl)-methyl-amine | 14497-54-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (2-[2]furyl-ethyl)-methyl-amine
• 英文别名: (2-[2]Furyl-aethyl)-methyl-amin；2-(N-Methyl-2-amino-ethyl)furan；[2-(2-furyl)ethyl]methylamine；Methyl-<β-(2-Furyl)-ethyl>-amin；2-(Furan-2-yl)-N-methylethan-1-amine；2-(furan-2-yl)-N-methylethanamine
• CAS: 14497-54-2
• 化学式: C₇H₁₁NO
• mdl: MFCD12776227
• 分子量: 125.17
• InChiKey: QYRROBPCVBPJJS-UHFFFAOYSA-N

物化性质

• 熔点：
  69-70 °C
• 沸点：
  69-70 °C(Press: 20 Torr)
• 密度：
  0.960±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  25.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2-[2]furyl-ethyl)-methyl-amine 在 盐酸 、 钯 作用下， 生成 N-methyl-2-tetrahydrofuran-2-yl-ethanamine
  参考文献：
  名称：

  Furyl- and Tetrahydrofuryl-alkylamines

  摘要：

  DOI：

  10.1021/jo01116a016
• 作为产物：
  描述：

  1-(2-糠酰)-2-硝基乙烯 在 lithium aluminium tetrahydride 、 乙醚 、 三氯乙醛 作用下， 生成 (2-[2]furyl-ethyl)-methyl-amine
  参考文献：
  名称：

  Furyl- and Tetrahydrofuryl-alkylamines

  摘要：

  DOI：

  10.1021/jo01116a016

文献信息

• THERAPEUTIC AGENT FOR CEREBRAL INFARCTION
  申请人：Nakao Akira

  公开号：US20120196824A1

  公开（公告）日：2012-08-02

  The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.

  这项发明提供了一种用于缺血性中风的治疗药物。该治疗药物具有如下式（I）的化学式，其中每个符号如本文所定义，或其药理学上可接受的盐，或其溶剂化物，作为活性成分。
• (2H)-3-benzazepin-2-ones, their pharmaceutical compositions and their
  申请人：Dr. Karl Tomae, GmbH

  公开号：US04737495A1

  公开（公告）日：1988-04-12

  The invention relates to new heteroaromatic amine derivatives of formula ##STR1## wherein A represents a --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--or ##STR2## group and B represents a methylene, carbonyl or thiocarbonyl group or A represents a --CO--CO or ##STR3## group and B represents a methylene group, in which the carbon atom marked x is linked to the phenyl nucleus, E represents a straight-chained alkylene group optionally substituted by an alkyl group, G represents a straight-chained alkylene group optionally substituted by an alkyl group, R.sub.1 represents a hydrogen, fluorine, chlorine or bromine atom, a trifluoromethyl, nitro, amino, alkylamino, dialkylamino, alkyl, alkylmercapto, hydroxy, alkoxy or phenylalkoxy group, R.sub.2 represents a hydrogen, chlorine or bromine atom or a hydroxy, alkoxy, phenylalkoxy or alkyl group or R.sub.1 and R.sub.2 together represent an alkylenedioxy group, R.sub.3 represents a hydrogen atom, an alkenyl group, an alkyl or phenylalkyl group, and Het represents a 5- or 6-membered heteroaromtic ring bonded via a carbon or nitrogen atom, which contains an oxygen, sulphur or nitrogen atom, two nitrogen atoms or a nitrogen atom and an oxygen or sulphur atom, and onto which additionally a phenyl ring can be condensed, in which case the bond can also be via the phenyl nucleus, or an imidazo[1,2-a]pyridyl group wherein the carbon structure of the above-mentioned groups can be substituted by a methylenedioxy or ethylenedioxy group or can be mono- or disubstituted by a halogen atom or an alkyl, hydroxy, alkoxy, phenylalkoxy, phenyl, dimethoxyphenyl, nitro, amino, acetylamino, carbamoylamino, N-alkyl-carbamoylamino, hydroxymethyl, mercapto, alkylmercapto, alkylsulphinyl, alkylsulphonyl, alkylsulphonyloxy, alkylsulphonylamino, alkoxycarbonylmethoxy, carboxymethoxy or alkoxymethyl group, and at the same time any imino group present in the above-mentioned heteroaromatic groups can be substituted by an alkyl, phenylalkyl or phenyl group, the N-oxides and the acid addition salts thereof with inorganic or organic acids, which have valuable pharmacological properties, particularly the effect of lowering heart rate and oxygen requirement of the heart. They can be used to treat sinus tachycardia or ischaemic heart disease.

  本发明涉及新的杂芳胺衍生物，其化学式为##STR1##其中A代表--CH.sub.2 --CH.sub.2 --，--CH.dbd.CH--或##STR2##基团，B代表一个亚甲基、羰基或硫代羰基基团，或者A代表--CO--CO或##STR3##基团，B代表一个亚甲基基团，其中标有x的碳原子与苯环相连，E代表一条直链烷基基团，该基团可选择由烷基基团取代，G代表一条直链烷基基团，该基团可选择由烷基基团取代，R.sub.1代表氢、氟、氯或溴原子，三氟甲基、硝基、氨基、烷基氨基、二烷基氨基、烷基、烷基硫醇基、羟基、烷氧基或苯基氧基基团，R.sub.2代表氢、氯或溴原子或羟基、烷氧基、苯基氧基或烷基基团，或者R.sub.1和R.sub.2一起代表烷二氧基基团，R.sub.3代表氢原子、烯基基团、烷基或苯基烷基基团，Het代表通过碳或氮原子键合的含有氧、硫或氮原子、两个氮原子或一个氮原子和一个氧或硫原子的5-或6-成员杂芳环，其上还可以附加一个苯环，并且在这种情况下，键合也可以通过苯环核心进行，或者是一种咪唑并[1,2-a]吡啶基团，在上述基团的碳结构可以被甲二氧基或乙二氧基基团取代，或者可以被卤原子或烷基、羟基、烷氧基、苯基氧基、苯基、二甲氧基苯基、硝基、氨基、乙酰氨基、氨基甲酰氨基、N-烷基-氨基甲酰氨基、羟甲基、硫醇基、烷基硫醇基、烷基磺酰基、烷基磺酰氧基、烷基磺酰氨基、烷氧羰基甲氧基、羧基甲氧基或烷氧甲基基团单取代或双取代，同时上述杂芳基团中存在的任何亚胺基团可以被烷基、苯基烷基或苯基取代，以及它们的N-氧化物和与无机或有机酸形成的酸加合盐，具有有价值的药理性能，特别是降低心率和心脏氧需求的作用。它们可用于治疗窦性心动过速或缺血性心脏病。
• Tricyclic Guanidine Derivatives as Sodium-Proton Exchange Inhibitors
  申请人：Lal Bansi

  公开号：US20070299051A1

  公开（公告）日：2007-12-27

  Guanidine derivatives having a condensed tricyclic ring of formula 1: are disclosed, wherein U is C(O), CR a R b , O, NR a or S(O) m ; V is CR a R b or NR a ; W is S(O) m ; wherein R a is H, alkyl, cycloalkyl, alkenyl or aralkyl; R b is H, alkyl, OH, OR a or OCOR a , and m is the integer 0, 1 or 2; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein with the proviso that at least one of R1, R2, R3, R4, R5, R6, R7 or R8 is guanidino or guanidino carbonyl. These derivatives are sodium-proton exchange inhibitors and are useful as medicaments for the treatment of, for example, organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy, hypertension, cell proliferative disorders and diabetes.

  本发明公开了具有式1的紧凑三环环的胍衍生物，其中U为C（O），CRaRb，O，NRa或S（O）m; V为CRaRb或NRa; W为S（O）m;其中Ra为H，烷基，环烷基，烯基或芳基烷基; Rb为H，烷基，OH，ORa或OCORa，m为整数0、1或2; R1、R2、R3、R4、R5、R6、R7和R8如定义所述，但至少其中之一为胍基或胍基羰基。这些衍生物是钠-质子交换抑制剂，可用作治疗与缺血再灌注相关的器官疾病、心律失常、心肌肥大、高血压、细胞增殖性疾病和糖尿病等疾病的药物。
• Methods of using MEK inhibitors
  申请人：Lamb Peter

  公开号：US20080166359A1

  公开（公告）日：2008-07-10

  The present invention provides methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments.

  本发明提供了一种通过给予I式化合物或其药学上可接受的盐或溶剂与其他癌症治疗相结合的方法来治疗癌症的方法。
• Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases
  申请人：Aay Naing

  公开号：US20100249096A1

  公开（公告）日：2010-09-30

  Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.

  本发明公开了式(I)的化合物及其药学上可接受的盐和溶剂化物。这些化合物是MEK抑制剂，可用于治疗增生性疾病，如癌症。本发明还公开了含有这些化合物的制药组合物，以及使用本发明的化合物和组合物治疗癌症的方法。